| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.97 | 0.01 (+0.20%) | 3.65 - 13.45 | 123.7 thousand (Below Avg) |
Market data as of 4:00PM 06/17/13. Quotes are delayed by at least 15 min.
| Open | 4.98 |
|---|---|
| Previous Close | 4.96 |
| Day's Range | 4.93 - 5.12 |
| Market Cap | 128.9M |
| Avg Volume (10 Day) | 198.3K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.58 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program
PR Newswire - Thursday 06/13/2013 7:00 AM ET
Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
PR Newswire - Friday 05/31/2013 7:00 AM ET
Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
PR Newswire - Tuesday 05/28/2013 7:00 AM ET
Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
PR Newswire - Thursday 05/23/2013 7:00 AM ET
Omeros to Present at Two Upcoming Conferences
PR Newswire - Wednesday 05/22/2013 7:00 AM ET
| OMER | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 17.57% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 22.88 |
| Company | Last | Change |
|---|---|---|
| Ambit Biosciences Corp | 7.19 | -4.13% |
| Cell Therapeutics Inc | 1.25 | +5.93% |
| Aveo Pharmaceuticals Inc | 2.65 | +1.92% |
| Inovio Pharmaceuticals Inc | 0.68 | +1.49% |
| ImmunoCellular Therapeutics Ltd | 2.17 | -0.91% |
Data is delayed by at least 15 min.